Crispr Therapeutics is trading at $51.21 (4% down) as its multi-day slide continues following recent valuation debates and profit-taking in high-beta biotech.
- The stock remains under pressure as Casgevy label expansion headlines have prompted a reassessment of previously bullish market expectations.
- Broader weakness in the biotech sector and risk assets is being driven by heightened geopolitical tensions and a softer Nasdaq.